Renzapride

Drug Profile

Renzapride

Alternative Names: ATL-1251; AZM 112; BRL-24924

Latest Information Update: 09 Feb 2017

Price : $50

At a glance

  • Originator GlaxoSmithKline
  • Developer Alizyme; EndoLogic; GlaxoSmithKline
  • Class Benzamides; Gastrokinetics; Heterocyclic bicyclo compounds; Irritable bowel syndrome therapies; Small molecules
  • Mechanism of Action Serotonin 3 receptor antagonists; Serotonin 4 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Gastro-oesophageal reflux; Gastroparesis; Irritable bowel syndrome

Most Recent Events

  • 04 Jan 2017 EndoLogic acquires worldwide rights to renzapride for development in gastroparesis
  • 04 Jan 2017 EndoLogic plans a phase II trial for Gastroparesis in USA
  • 23 Apr 2008 Discontinued - Phase-III for Irritable bowel syndrome in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top